GSK’s Viehbacher Charged To “Adapt” Sanofi-Aventis To New Realities

The backdrop for the change in command at Sanofi-Aventis is a string of product development setbacks stretching back to Zimulti (rimonabant) in June 2007, and more recently including the antidepressant amibegron, the gastric cancer agent S-1, the refractory ovarian cancer agent aflibercept and saredutant for major depression

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet